Source: Pentax C2 CryoBalloon Acquisition Announcement
source confidence: Medium status: Useful updated 2026-05-09
Summary
October 2025 press-release coverage announcing Merit Medical Systems' asset purchase of the C2 CryoBalloon gastrointestinal cryotherapy product line from Pentax Medical, with manufacturing transferring to South Jordan, Utah.
Useful Claims
- Merit Medical (NASDAQ: MMSI) acquired Pentax Medical's C2 CryoBalloon technology in October 2025.
- Manufacturing of the C2 CryoBalloon line is being transferred into Merit's South Jordan facility.
- The transaction is consistent with Merit's broader pattern of acquiring adjacent interventional technologies and integrating them into its Utah footprint.
Verbatim
"Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced it has signed a definitive asset purchase agreement with Pentax of America, Inc., a subsidiary of PENTAX® Medical, Inc., to acquire the C2 CryoBalloon™ device and related technology." — Press release, lead
"Over the next few months, Merit plans to transfer product manufacturing to its facility in South Jordan, Utah." — Press release, body
"The closing of the proposed transaction is expected to occur during the fourth quarter of 2025, subject to the receipt or waiver (in accordance with the provisions of the asset purchase agreement) of certain customary closing conditions." — Press release, lead
Reliability Notes
Press releases are leads, not neutral evidence. Reliable for what each party publicly committed to; not reliable for forward-looking financial or clinical claims. The Utah Business republication is a content-syndication channel rather than independent reporting.